生物医药公司Repertoire Immune Medicines近日宣布，已与全球制药巨头礼来(Eli Lilly)达成一项重要战略合作协议。双方将携手研发针对自身免疫性疾病的耐受性疗法，这一合作旨在通过创新技术平台探索免疫系统调节的新途径。
此次合作将结合Repertoire在T细胞受体图谱和免疫耐受技术方面的专长，与礼来在自身免疫疾病治疗领域的深厚研发经验。双方计划通过联合研究加速新型疗法的开发进程，为类风湿关节炎、红斑狼疮等自身免疫疾病患者提供潜在的全新治疗选择。
该战略合作体现了生物技术公司与大型药企优势互补的创新模式。通过资源共享和技术协同，双方有望在免疫耐受治疗领域实现突破性进展，为全球数亿自身免疫疾病患者带来新的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.